Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.
Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...
Sanofi now said the agreement follows completion ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Highlights,Zacks Research adjusted its Q2 2025 EPS estimate for Sanofi to $0.93, slightly decreasing from a prior prediction ...
Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ...
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.
Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...
Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP ...
Product revenues from Aldurazyme totaled $39 million, down 9% year over year, likely due to the unfavorable timing of order fulfillment to Sanofi SNY. BioMarin signed a collaboration agreement ...
The 2023 revenues had benefited from a 30 million euros milestone payment from Boehringer Ingelheim associated with survodutide and $10 million milestone payment from Sanofi associated with ...